X4 Pharmaceuticals Inc (XFOR) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.55 (+1.43%), Market cap $0.37B, 52-week low–high $1.42 ~ $4.66.
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporati
Financial statements, price targets, institutional (13F) holdings and related news for X4 Pharmaceuticals Inc are updated in real time on BlackAll Trade.
X4 Pharmaceuticals Inc trades at $3.55 (+1.43%). Real-time quotes and charts are available on BlackAll Trade.
X4 Pharmaceuticals Inc has a market cap of about $0.37B.
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It off